Trial Profile

A Phase 2 clinical study of NS002 intranasal epinephrine powder for the treatment of anaphylaxis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Dec 2025 New trial record
18 Nov 2025 According to a Nasus Pharma media release, first patient from this trial has been dosed in Canada.Interim results from this trial are expected in the first quarter of 2026.
06 Nov 2025 According to a Nasus Pharma media release, the Health Canada clearance confirms the acceptability of the proposed trial design, supporting safety data, and manufacturing information, and enables Nasus to advance towards its planned Phase 2 clinical study. Company look forward to initiating the study as soon possible.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com